AMSTERDAM and NEW YORK, Nov. 13,
2017 /PRNewswire/ -- Royal Philips (NYSE: PHG,
AEX: PHIA), a global leader in health technology, today announced
that it will be showcasing its integrated vascular solutions
comprising interventional X-ray systems, diagnostic and therapeutic
devices, planning and navigation software and services at the 2017
VEITHsymposium (VEITH) in New York, New
York (November 14 - 18, 2017).
At the symposium, Philips will launch PVDandMe.com, a new patient
education website providing resources on peripheral vascular
disease (PVD) to help patients improve their quality of life.
One in every 20 Americans over the age of 50 has peripheral
artery disease (PAD), a common peripheral vascular disease. If left
untreated, PAD can become a serious condition linked to severe
complications and an increased risk of a heart attack and stroke
[1]. Since peripheral vascular disease often has few symptoms, the
need for understanding of the condition and integrated solutions
offering personalized care is extremely critical. Philips' new
patient website provides information about common peripheral
vascular disease conditions, signs, symptoms, causes and risk
factors. Philips also has launched a complementary PVD site for
healthcare providers, Philips.com/PVDresources, with tools to help
clinicians establish an office-based laboratory, improving practice
workflow and educating colleagues.
"The new Philips unbranded, patient-focused PVD website is a
rich resource to aid patients with peripheral vascular disease in
understanding their condition to seek treatment to improve their
quality of life," said Dr. Raghu
Kolluri, MS, MD, RVT, System Medical Director of Vascular
Medicine at OhioHealth. "By offering extensive information from
treatment options to the physician locator tool, Philips is helping
patients better understand their diagnosis and seek appropriate
treatment."
At VEITH, Philips will showcase its leading portfolio of
interventional imaging systems, devices, software, and services.
With its recent acquisition of Spectranetics in August 2017, Philips' expanded range of therapy
devices for peripheral vascular disease at this year's symposium
will include:
- Azurion is the next generation image-guided therapy platform,
which enables clinicians to easily and confidently perform a range
of routine and complex procedures, helping them to optimize
interventional lab performance and provide superior care.
- Stellarex drug-coated balloon delivers top-tier clinical
results for common to complex patients. As the only commercially
available drug-coated balloon with two reported randomized
controlled trials, Stellarex has demonstrated durability with
consistently high patency rates in a wide range of patients.
- The Phoenix atherectomy system, which combines the benefits of
existing atherectomy systems, delivers a unique, hybrid [2]
atherectomy option to help physicians tailor the treatment approach
for each patient.
- SymphonySuite is Philips' comprehensive program that includes a
robust set of tools to support efforts in opening, growing and
maintaining office based lab solutions.
"Our recent acquisition of Spectranetics has accelerated our
expansion into therapy devices, complementing our image-guided
therapy portfolio that is designed to help clinicians perform
efficient and effective treatments," said Christopher Barys, Image Guided Therapy Devices
Business Leader for Philips. "Additionally, the launch of the
patient resource and clinician webpage demonstrates how we are
working to improve patient care and further our goal to help
clinicians decide, guide, treat and confirm the right therapies for
their patients."
See the calendar of events, as well as general information about
Philips' presence at the show here. Visit the Philips and Philips
Spectranetics booths (#426 and #308) and the Philips Pavilion in
the Nassau suite to experience
innovative solutions that deliver the full health continuum in the
vascular space. Follow the #VEITH17 conversation on
@PhilipsLiveFrom throughout the event.
[1] National Institutes of Health, Facts About Peripheral
Arterial Disease (P.A.D.), NHLBI.NIH.gov, September 2017
[2] Directional cutting ability only available with Phoenix 2.4mm deflecting catheter
For further information, please contact:
Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31 6-22698001
E-mail: fabienne.van.der.feer@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving
people's health and enabling better outcomes across the health
continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips' health
technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 73,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
View original content with
multimedia:http://www.prnewswire.com/news-releases/philips-showcases-integrated-vascular-solutions-at-veith-2017-300554721.html
SOURCE Royal Philips